Bristol-Myers Squibb has signed a definitive agreement to acquire Adnexus Therapeutics for $430 million in cash. Adnexus has developed a new therapeutic class of biologics called Adnectins, which BMS plans to use to advance its biologics strategy in several therapeutic areas. The program includes a Phase I oncology biologic, Angiocept. Adnexus Therapeutics will become a subsidiary of BMS and remain based in Waltham, MA.     Under the terms of the agreement BMS will acquire all of Adnexus&#821...